CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS

CONMED Corp

2025-FY EPS reported $1.51 revenue$1,374,724,000

Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.
FY2025 sales $1.3747B (+5.2%); GAAP EPS $1.51 vs $4.25, adjusted EPS $4.59 vs $4.17.
FY2026 guidance: revenue $1.345B-$1.375B (organic constant-currency growth 4.5%-6% ex-gastro), adj. EPS $4.30-$4.45.
International Q4 revenue +17% (reported) vs domestic +1.4%; Orthopedic Surgery segment +13.2%.
GAAP results weighed by ~$60M in Q4 operating charges including optimization and product rationalization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.